Metformin for treatment of antipsychotic-induced weight gain: A randomized, placebo-controlled study
Introduction
Almost all antipsychotics can induce weight gain. Citrome reported that the proportions of patients who gained at least 7%, 15% or 25% of their baseline weight with long-term exposure to antipsychotic were 64%, 32% and 12%, respectively (Citrome et al., 2011). So, weight gain has become a main concern for the antipsychotic treatment because weight gain not only influence medication adherence but also are associated with substantial medical morbidity (Smith et al., 2005). For example, people with severe mental illness die up to 3 decades earlier than the general population. Heart disease is a leading cause of death in these patients (Colton and Manderscheid, 2006, Miller et al., 2006). One of the major risk factors for heart disease and early death in these patients is weight gain.
The mechanisms which produce weight gain in many antipsychotics are not well understood, but are associated with central histamine H1 antagonism, increased appetite, and/or the direct impairment of metabolic regulation through the alteration of insulin sensitivity (Kroeze et al., 2003, Matsui-Sakata et al., 2005). At present, there is a relative dearth of interventions to control or reverse antipsychotic-induced weight gain. A variety of pharmacological agents have been studied in an attempt to reverse antipsychotic-induced weight gain (Henderson et al., 2005, Hester and Thrower, 2004), but current evidence is insufficient to support any particular pharmacological treatment.
Metformin is the most widely prescribed insulin sensitizer for the management of type 2 diabetes. Some studies found that metformin can improve weight gain and insulin resistance that were induced by antipsychotics in schizophrenia patients, and reduce metabolic syndrome or type 2 diabetes (Kitabchi et al., 2005, Klein et al., 2006, Rasouli et al., 2007, Wu et al., 2008b).
To our knowledge, there have been few double-blind, placebo-controlled studies to assess the efficacy of metformin for antipsychotic-induced weight gain among patients with schizophrenia. In this article, we report a 12-week randomized, double-blind, placebo-controlled trial that tested the efficacy of metformin attenuating antipsychotic-induced weight gain in first episode schizophrenia patients.
Section snippets
Participants
Patients aged 18 through 60 years with a first psychotic episode of schizophrenia diagnosed in accordance with criteria set out in the Diagnostic and Statistical Manual of Mental Disorders—Fourth Edition (DSM-IV) were eligible for our study (American Psychiatric Association, 1994). The diagnosis of schizophrenia was determined by the Structured Clinical Interview of DSM-IV Axis I Disorders, Clinical Version, during the screening phase (First et al., 1997). Other enrollment criteria included that
Demographic and basic descriptive data
Seventy-two patients entered the trial. Six withdrew from the study within the first 4 weeks because of nausea (two metformin patients and one placebo patient) and hospitalization for exacerbation of psychosis (two metformin patients and one placebo patient). This resulted in 66 (91.7%) patients who were included in the study. The two treatment groups did not differ significantly in demographic or clinical characteristics and baseline measurements (Table 1, Table 2).
The findings presented in
Discussion
This randomized placebo-controlled study represents an attempt to explore the effectiveness of metformin on preventing further weight exacerbation or causing weight loss in patients with schizophrenia who had experienced substantial weight gain during the first year of treatment with antipsychotic agents. In this 12-week study, we found body weight and body mass index decreased significantly in the metformin group and increased in the placebo group. Accordingly, significantly more patients in
Role of funding source
This article was supported by research grant from the Scientific Research Fund of Liaoning Science and Technology Agency, China (No. 2011225020).
I have not signed an agreement with any sponsor of the study reported in this article that has a clause which prevents me from publishing both positive and negative results, from collaborating with other investigators to pool data across sites, or that forbids me from publishing without the approval of the sponsor.
Contributors
- 1.
Guarantor of integrity of the entire study: Man Wang and Jian-hua Tong
- 2.
Study concepts and design: Man Wang and Jian-hua Tong and Gang Zhu
- 3.
Literature research: Gang Zhu and Guang-ming Liang
- 4.
Clinical studies: Man Wang and Gang Zhu and Guang-ming Liang and Hong-fei Yan and Xiu-zhen Wang
- 5.
Experimental studies/data analysis: Jian-hua Tong and Gang Zhu
- 6.
Statistical analysis: Man Wang and Jian-hua Tong
- 7.
Manuscript preparation: Man Wang and Gang Zhu and Guang-ming Liang and Hong-fei Yan and Xiu-zhen Wang
- 8.
Conflicts of interest
Dr. Man Wang reported no biomedical financial interests or potential conflicts of interest in relation to the work described in the manuscript.
Dr. Jian-hua Tong reported no biomedical financial interests or potential conflicts of interest in relation to the work described in the manuscript.
Dr. Gang Zhu reported no biomedical financial interests or potential conflicts of interest in relation to the work described in the manuscript.
Dr. Guang-ming Liang reported no biomedical financial interests
Acknowledgments
This article was supported by research grant from the Scientific Research Fund of Liaoning Science and Technology Agency, China (No. 2011225020).
References (25)
- et al.
Metformin-associated lactic acidosis treated with continuous renal replacement therapy
Clin. Ther.
(2006) - et al.
Receptor occupancy-based analysis of the contribution of various receptors to antipsychotic-induced weight gain and diabetes mellitus
Drug Metab. Pharmacokinet.
(2005) - et al.
Metformin-associated lactic acidosis
Ann. Fr. Anesth. Rèanim.
(2006) Diagnostic and Statistical Manual of Mental Disorders
(1994)Scale for Assessment of Negative and Positive Symptoms
(1984)- et al.
Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder
Clin. Drug Investig.
(2011) - et al.
Metformin prevents the development of acute lipid-induced insulin resistance in the rat through altered hepatic signaling mechanisms
Diabetes
(2004) - et al.
Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states
Prev. Chron. Dis.
(2006) - et al.
Structured Clinical Interview for DSM-IV Axis I Disorders— Clinician Version (SCID-CV)
(1997) - et al.
The effect of metformin on the metabolic abnormalities associated with upperbody fat distribution
Diabetes Care
(1996)
ECDEU Assessment Manual for Psychopharmacology, Revised
The homeostasis model in the San Antonio heart study
Diabetes Care
Cited by (68)
Association Between Weight Promoting Medication Use and Weight Status Among Children and Adolescents in the United States
2023, Academic PediatricsCitation Excerpt :Still, it is difficult to predict the risk of weight gain with the long term use of any specific antidepressant.37 However, metformin, a non-WPM antidepressant can be prescribed to prevent and control antipsychotic and antidepressant-induced weight gain.38,39 There is a great need for a more longitudinal assessment of this association.
The effect of metformin on indomethacin-induced gastric ulcer: Involvement of nitric oxide/Rho kinase pathway
2021, European Journal of PharmacologyCitation Excerpt :Metformin is considered the first-line treatment for all newly diagnosed patients with type 2 diabetes mellitus (American Diabetic Association, 2014b). Apart from its known role in glycemic control, Metformin in the last decade underwent a second career as efficacious treatment of polycystic ovary syndrome by reducing insulin resistance which is the underlying cause of both polycystic ovary syndrome and type 2 diabetes (Bushe et al., 2009; Wang et al., 2012). In non-diabetic patients, obesity is also linked to insulin resistance so improving insulin sensitivity may result in weight reduction using metformin therapy without inducing unbearable side effects (Lustig, 2002; Odeleye et al., 1997; Sigal et al., 1997).
The Diagnostic Workup, Screening, and Treatment Approaches for Patients with Delusional Infestation
2023, Dermatology and TherapyOptimizing Therapy Selection and Sequencing in Schizophrenia
2023, Journal of Clinical PsychiatryPharmacological interventions for prevention of weight gain in people with schizophrenia
2022, Cochrane Database of Systematic Reviews